Merck KGaA, Darmstadt, Germany, a science and technology company, and SpringWorks Therapeutics Inc., a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, have entered into a definitive agreement for Merck KGaA, Darmstadt, Germany, to acquire SpringWorks. “The agreed acquisition of SpringWorks is a major step in our active portfolio strategy to position our company as a globally diversified, innovation and technology powerhouse. For our Healthcare sector, it...